Drug Discovery Informatics Market Worth $3.5 Billion in 2025 - Exclusive Report by MarketsandMarkets™
CHICAGO, April 8, 2020 /PRNewswire/ -- According to the new market research report "Drug Discovery Informatics Market by Function (Target Data, Sequencing Data Analysis, Docking) Solution (Software, Services), Application (Drug Development), End User (Pharmaceutical, Biotechnology, Contract Research Organizations) – Global Forecast to 2025", published by MarketsandMarkets™, the global Drug Discovery Informatics Market is projected to reach USD 3.5 billion in 2025 from USD 2.2 billion in 2020, at a CAGR of 9.3% during the forecast period.
Download PDF Brochure:
Market growth is largely driven by factors such as the rising R&D expenditure, growing support for research, especially in the area of rare diseases, and the increasing use of informatics in drug discovery.
By function, the sequencing and target data analysis segment accounted for the largest share for the drug discovery informatics market.
The sequencing and target data analysis segment accounted for the largest share of the drug discovery informatics market for the function segment of the market in 2019. The large share of this segment can be attributed to increased application for sequencing analysis for the new drug entity and ease of handling of information from different sources and different domains.
Browse in-depth TOC on "Drug Discovery Informatics Market"
124 – Tables
32 – Figures
140 – Pages
By the end-user, the pharmaceutical companies segment accounted for the largest share of the drug discovery informatics market.
The pharmaceutical companies segment accounted for the largest share of the drug discovery informatics market in 2019, and pharmaceutical companies are using these informatics software extensively for pre-clinical research & development, target identification, compound screening and lead identification, and streamlining their drug discovery process which is the major factor for driving the growth of this segment
By application, the drug development segment accounted for the largest share of the drug discovery informatics market.
The drug development segment accounted for the largest share of the drug discovery informatics market in 2019, large share of this segment is primarily attributed to the increasing investments in the research and development of new drug molecules and the growing need for time and cost optimization for drug discovery and development.
Get 10% Customization on this Research Report:
North America accounted for the largest share of the market.
The drug discovery informatics market is divided into four major regions-North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the global drug discovery informatics market, closely followed by Europe. The large share of North America in the global market can be attributed to the presence of well-established CROs, rising R&D expenditure by pharmaceutical and biopharmaceutical companies
The Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Factors such as the rapid growth in the pharmaceutical and biopharmaceutical industry, rising number of CROs, and the presence of less-stringent regulations for drug discovery processes
The major companies in the drug discovery informatics market include Jubilant Life Sciences Limited (India), Charles River Laboratories (US), IBM (US), Clarivate Analytics (US), and Accenture (Ireland).
Browse Adjacent Markets: Healthcare IT Market Research Reports & Consulting
Get Special Pricing on Bundle Reports:
Browse Related Reports:
Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Sanjay Gupta
630 Dundee Road
Northbrook, IL 60062
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/drug-discovery-informatics-market.asp
Visit Our Website: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/drug-discovery-informatics.asp